Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837666 | 0.88 | CYP3A4 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL29950180 | 0.86 | CYP2C9 (0.43) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2363613 | 0.86 | CYP2C9 (0.43) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2837668 | 0.85 | CYP3A4 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2839107 | 0.84 | CYP2C9 (0.44) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2838699 | 0.84 | CYP2C9 (0.44) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2837475 | 0.83 | CYP3A4 (0.42) | CYP2C9CYP3A4CYP2C19KCNH2CYP2C8 | |
| SCHEMBL2840738 | 0.82 | CYP2C9 (0.42) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2841478 | 0.82 | CYP3A4 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2CYP2C8 | |
| SCHEMBL2846114 | 0.81 | CYP3A4 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | claimed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | claimed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | CYP2C9 129/4885CYP3A4 38/4885CYP2C19 117/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | CYP2C9 129/4885CYP3A4 38/4885CYP2C19 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.